Microbiota state of the gastro-intestinal tract of laboratory animals with signs of metabolic dysbiosis during treatment with experimental medical drug

Objective. The work was performed with the purpose to study microbiota state of the gastro-intestinal tract (GIT) of C57Bl/6 mice with signs of metabolic dysbiosis (MD) induced with the use of fructose solution or with poloxamer 407 (P 407), during treatment with combination of sodium polyprenylphosphate (PPP) and beta-sitosterol (BSS). Materials and Methods. MD was induced in mice with drinking 20 per cent water fructose solution. MD was also induced in mice by intraperitoneal use of P 407 at the dose of 500 mg/kg two times per week during ten weeks. The mice of experimental groups received intragastrically combination of PPP and BSS preparations (0,2 ml of the suspension per mouse). Medical scheme consisted in use of preparations five times per week starting after one month from the first day of fructose drinking or of P 407 use and prolonging for one month else. The quantity of viable bacteria in the probes obtained was measured by the direct passage of the material tested on elective or selective nutritional media with following count of colonies grown. Results. The drink of fructose solution or use of P 407 caused the changes of GIT microbiota state that confirmed development of signs of MD in mice. Treatment with PPP and BSS combination was shown to cause actual tendencies to restore the normal GIT microbiota state. Conclusion. Combination of PPP and BSS preparations seemed to be efficient as a novel approach to correction of GIT microbiota state perturbed due to pathogenesis of MD considered as one of the primary signs of metabolic syndrome in mice.

intestinal microbiota, metabolic dysbiosis, treatment

1. Drapkina O.M., Korneeva O. N. Gut microbiota and obesity: Pathogenetic relationships and ways to normalize the intestinal microflora. Terapevt. Arkhiv. 2016; 88(9): 135-42. (in Russ.) https://doi.org/10.17116/terarkh 2016889135-142.@@ Drapkina O. M., Korneeva O. N. Kishechnaya mikrobiota i ozhirenie. Patogeneticheskie vzaimosvyazi i puti normalizatsii kishechnoi mikroflory. Terapevt. arkhiv. 2016; 88(9): 135-42. https://doi.org/10.17116/terarkh 2016889135-142.

2. Kuznetsova E. E., Gorokhova V. G., Bogorodskaya S. L. The microbiota of intestine. The role in development of various pathologies. Klin. Lab. Diagnostika. 2016; 61(10): 723-6. (in Russ.) https://doi.org/10.18821/0869-2084-2016-61-10-723-726.@@ Kuznetsova E. E., Gorokhova V. G., Bogorodskaya S. L. Mikrobiota kishechnika. Rol' v razvitii razlichnykh patologii. Klin. lab. diagnostika. 2016; 61(10): 723-6. https://doi.org/10.18821/0869-2084-2016-61-10-723-726.

3. Oynotkinova O. Sh., Nikonov E. L., Gioeva I. A. The role of microbiota in pathogenesis of dyslipidemia and associated metabolic disorders. Evidence-Based Gastroenterology. 2017; 6(2): 29-34. (in Russ.) https://doi.org/10.17116/dokgastro 20176229-34.@@ Oinotkinova O. Sh., Nikonov E. L., Gioeva I. Z. Rol' mikrobioty kishechnika v patogeneze dislipidemii i assotsiirovannykh metabolicheskikh narushenii. Dokazat. gastroenterologiya. 2017; 6(2): 29-34. https://doi.org/10.17116/dokgastro 20176229-34.

4. Thursby E., Juge N.Introduction to the human gut microbiota. Biochem. J. 2017; 474(11): 1823-36. https://doi.org/10.1042/BCJ 20160510.

5. Grinevich V. N., Tkacheva O. N., Egshatyan L. V., Sas E. I., Efimov O. I. Contribution of the gut microbiota to the pathogenesis of insulin resistance. Profilakt Meditsina. 2015; 18(1): 54-8. (in Russ.) https://doi.org/10.17116/profmed 201518154-58.@@ Grinevich V. B., Tkacheva O. N., Egshatyan L. V., Sas E. I., Efimov O. I. Vklad kishechnoi mikrobioty v patogenez insulinorezistentnosti. Profilakt. meditsina. 2015; 18(1): 54-8. https://doi.org/10.17116/profmed 201518154-58.

6. Ussar S., Fujisaka S., Kahn C. R.Interaction between host genetics and gut microbiome in diabetes and metabolic syndrome. Molec. Metabolism. 2016; 5(9): 795-803. https://doi.org/10.1016/j.molmet. 2016.07.004.

7. Bukharin O. V., Ivanova E. V., Perunova N. B., Chainikova I. N. The role of bifidobacteria in formation of human immune homeostasis. Zh. Microbiol. (Moscow). 2015; 6: 98-104. (in Russ.)@@ Bukharin O. V., Ivanova E. V., Perunova N. B., Chainikova I. N. Rol' bifidobakterii v formirovanii immunnogo gomeostaza cheloveka. Zhurn. mikrobiol., epidemiol. i immunobiologii. 2015; 6: 98-104.

8. Kashukh Y. A., Ivashkin V. T. Probiotics, metabolism and the functional condition of cardio-vascular system.Russ. J. Gastroenterol., Hepatol., Coloproctology. 2016; 26(1): 8-14. (in Russ). https://doi.org/10.22416/1382-4376-2016-26-1-8-14.@@ Kashukh E. E., Ivashkin V. T. Probiotiki, metabolizm i funktsional'noe sostoyanie serdechno-sosudistoi sistemy. Ross. zhurn. gastroenterol., gepatol., koloproktologii. 2016; 26(1): 8-14. https://doi.org/10.22416/1382-4376-2016-26-1-8-14.

9. Mischke M., Plösch T. The gut microbiota and their metabolites: potential implications for the host epigenome. Adv. Exp. Med. and Biology. 2016; 902: 33-4. https://doi.org/10.1007/978-3-319-31248-4_3.

10. Kotrova A. D., Shishkin A. N., Semienova O. I., Slepykh L. A. The role of gut microbiota in the development of metabolic syndrome. Experimental and Clinical Gastroenterology. 2019; 172(12): 101-8. (in Russ). https://doi.org/10.31146/1682-8658-ecg-172-12-101-108.@@ Kotrova A. D., Shishkin A. N., Semenova O. I., Slepykh A. A. Rol' kishechnoi mikrobioty v razvitii metabolicheskogo sindroma. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019; 172(12): 101-8. https://doi.org/10.31146/1682-8658-ecg-172-12-101-108.

11. Brown K., Decoffe D., Molcan E., Gibson D. L. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012; 4: 1095-119. https://doi.org/10.3390/nu4081095.

12. Leshchenko D. V., Kostiuk N. V., Belyakova M. B., Egorova E. N., Miniaev M. V., Petrova M. B. Diet-induced animal models of metabolic syndrome. Upper Volga Med. J. 2015; 2: 34-9. (in Russ.)@@ Leshchenko D. V., Kostyuk N. V., Belyakova M. B., Egorova E. N., Minyaev M. V., Petrova M. B. Dieticheski indutsirovannye zhivotnye modeli metabolicheskogo sindroma. Verkhnevolzhskii medits. zhurnal. 2015; 14(2): 34-9.

13. Kavanagh K., Wylie A. T., Tucker K. L., Hamp T. J., Gharaibeh R. Z., Fodor A. A., Cullen J. M. Dietary fructose induces endotoxemia and hepatic injury in calorically controlled primates. Amer. J. Clin. Nutrition. 2013; 98(2): 349-57. https://doi.org/10.3945/ajcn.112.057331.

14. Mamikutty N., Thent Z. C., Sapri S. R., Sahruddin N. N., Mohd Yusof M. R., Haji Suhaimi F. The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. Biomed Res Int. 2014;2014:263897. https://doi.org/10.1155/2014/263897.

15. Reshetnyak M. V., Khirmanov V. N., Zybina N. N., Frolova M. Y., Sakuta G. A., Kudryavtsev B. N. Fructose-fed model of the metabolic syndrome: Pathogenetic relationships between metabolic disorders. Med. Acad. J. 2011; 11(3): 23-7. (in Russ.) https://doi.org/10.17816/MAI 11323-27.@@ Reshetnyak M. V., Khirmanov V. N., Zybina N. N., Frolova M. Yu., Sakuta G. A., Kudryavtsev V. N. Model' metabolicheskogo sindroma, vyzvannogo kormleniem fruktozoi: patogeneticheskie vzaimosvyazi obmennykh narushenii. Medits. akadem. zhurnal. 2011; 11(3): 23-7. https://doi.org/10.17816/MAI 11323-27.

16. Afineevskaya A. Yu., Mal’kov O.A., Govorukhina A. A. The role of intestinal microbiota in the pathogenesis of atherosclerosis and promising preventive measures. Zh. Med. Biol. Issledovaniy. 2020; 8(2): 184-93. (in Russ.) https://doi.org/10.37482/2542-1298-Z009.@@ Afineevskaya A. Yu., Mal'kov O. A., Govorukhina A. A. Rol' kishechnoi mikrobioty v patogeneze ateroskleroza i perspektivnye mery profilaktiki. Zhurn. mediko-biol. issledovanii. 2020; 8(2): 184-93. https://doi.org/10.37482/2542-1298-Z009.

17. Kaibysheva V. O., Nikonov E. L. Probiotics from the standpoint of evidence-based medicine. Evidence-Based Gastroenterology. 2019; 8(3): 45-54. (in Russ.) https://doi.org/10.17116/dokgastro 2019803145.@@ Kaibysheva V. O., Nikonov E. L. Probiotiki s pozitsii dokazatel'noi meditsiny. Dokazat. gastroenterologiya. 2019; 8(3): 45-54. https://doi.org/10.17116/dokgastro 2019803145.

18. Tursunova N. V., Klinnikova M. G., Tornuev Y. V., Lushnikova E. L. Plant polyproenols as a prospective class of compounds stimulating the regenerative processes. Modern Probl. Sci. Education. 2019; 4: 141-52. (in Russ.) https://doi.org/10.17513/spno.28977.@@ Tursunova N. V., Klinnikova M. G., Tornuev Yu. V., Lushnikova E. L. Rastitel'nye poliprenoly kak perspektivnyi klass soedinenii, stimuliruyushchikh regeneratornye protsessy. Sovrem. probl. nauki i obrazovaniya. 2019; 4: 141-52. https://doi.org/10.17513/spno.28977.

19. Sanin A. V., Ganshina I. V., Sudiyna G. F. et al. Phosphorilated polyprenols - a novel class of compounds with anti-inflammatory and bronchial spasmolytic activity. Infect. Immunity. 2011; 1(4): 355-60. (in Russ.)@@ Sanin A. V., Ganshina I. V., Sud'ina G. F. i dr. Fosforilirovannye poliprenoly - novyi klass soedinenii s protivovospalitel'noi i bronkholiticheskoi aktivnost'yu. Infektsiya i immunitet. 2011; 1(4): 355-360.

20. Narovlyansky A. N., Pronin A. V., Sanin A. V. et al. Isoprenoids: Polyprenols and Polyprenyl Phosphates as Physiologically Important Metabolic Regulators. Nova Science Publishers, Inc, NY, USA, 2018. - 183 p.

21. Khuchieva M. A., Perova N. V., Akhmedzhanov N. M. Plant sterols and stanols as dietary factors reducing hypercholesterolemia by inhibiting intestinal cholesterol absorption. Cardiovasc. Ther. Prevention. 2011; 10(6): 124-32. (in Russ.) https://doi.org/10.15829/1728-8800-2011-6-124-132.@@ Khuchieva M. A., Perova N. V., Akhmedzhanov N. M. Rastitel'nye steriny i stanoly kak pishchevye faktory, snizhayushchie giperkholesterinemiyu putem ingibirovaniya vsasyvaniya kholesterina v kishechnike. Kardiovask. terapiya i profilaktika. 2011; 10(6): 124-32. https://doi.org/10.15829/1728-8800-2011-6-124-132.